Biosimilar Tipping Point: Five Questions For Henlius CEO

 
• By Brian Yang

Now valued at close to $3bn, Henlius is one of the largest biotech unicorns in China. CEO Scott Liu sat down with Scrip in an exclusive interview to discuss biosimilar development in China, emerging market expansion plans, and its venture into immuno-oncology combo strategy.

China flag with arrow graph going up showing strong economy and shares rise. Profit and success. Isolated vector illustration.
CEO Of China's Henlius Talks Biosimilar Development And Emerging Markets Strategy • Source: Shutterstock

More from China

More from Focus On Asia